<p><strong>Cardio Diagnostics Holdings Inc.</strong> (NASDAQ: CDIO) 週四宣佈了一項 重大國際合作。</p>
<p>Cardio Diagnostics、<strong>Aimil Ltd.</strong> 和 <strong>Dr. Lal PathLabs Ltd</strong>. 揭示了一項將 PrecisionCHD 冠狀動脈測試引入印度的協議。</p>
<p>此次合作標誌着 Cardio Diagnostics 首次在美國以外擴展，目標是一個心臟病發病率上升的國家。</p>
<p>該測試結合了表觀遺傳學、遺傳學和人工智能，從血樣中檢測分子水平的冠狀動脈心臟病。</p>
<h2><strong>臨牀優勢</strong></h2>
<p>PrecisionCHD 能夠識別傳統血管造影通常漏掉的阻塞性和非阻塞性冠狀動脈心臟病形式。</p>
<p>印度的冠狀動脈心臟病發病率在某些城市人羣中高達 13%，凸顯了緊急篩查的需求。</p>
<p>合作伙伴已開始將該測試整合到 Dr. Lal PathLabs 的臨牀和實驗室網絡中，遵循印度的臨牀指南。</p>
<p>在整合和監管對接後，該集團預計將在 2026 年實現更廣泛的商業部署。</p>
<h2><strong>高管見解</strong></h2>
<p>Cardio Diagnostics 首席執行官兼聯合創始人 <strong>Dr. Meesha Dogan</strong> 表示，此次合作促進了對尖端心血管護理的公平獲取。</p>
<p>Aimil 執行董事 <strong>Dr. Mallika Kapur</strong> 表示，該項目加強了印度對先進心臟診斷的獲取。</p>
<p>Dr. Lal PathLabs 首席執行官 <strong>Shankha Banerjee</strong> 表示，該測試將幫助臨牀醫生更早地發現疾病並量身定製治療方案。</p>
<p><strong>CDIO 股價動態：</strong> Cardio Diagnostics 的股票在週四發佈時下跌 15.77%，報 $2.35。該股票交易於新的 52 周低點，根據 Benzinga Pro 數據。</p>
<p><em>圖片來源於 Shutterstock</em></p>

CDIO

<p>Cardio Diagnostics 已與 Aimil Ltd.和 Dr. Lal PathLabs 合作，在印度推出 PrecisionCHD 測試，旨在應對該國高發的心臟病率。這標誌着 Cardio Diagnostics 首次國際擴張，利用人工智能和表觀遺傳學從血液樣本中檢測冠心病。該測試旨在改善早期檢測和治療個性化。與 Dr. Lal PathLabs 網絡的整合正在進行中，預計將在 2026 年實現更廣泛的部署。Cardio Diagnostics 的股價下跌 15.77%，至 2.35 美元，創下 52 周新低</p>

<p><strong>Cardio Diagnostics Holdings Inc.</strong> (NASDAQ: CDIO) announced a major international partnership on Thursday.</p>
<div class="lb-trans"><p><strong>Cardio Diagnostics Holdings Inc.</strong> (NASDAQ: CDIO) 週四宣佈了一項 重大國際合作。</p>
</div><p>Cardio Diagnostics, <strong>Aimil Ltd.</strong> and <strong>Dr. Lal PathLabs Ltd</strong>. revealed a deal to bring the PrecisionCHD coronary test to India.</p>
<div class="lb-trans"><p>Cardio Diagnostics、<strong>Aimil Ltd.</strong> 和 <strong>Dr. Lal PathLabs Ltd</strong>. 揭示了一項將 PrecisionCHD 冠狀動脈測試引入印度的協議。</p>
</div><p>The collaboration marks Cardio Diagnostics' first expansion outside the United States, targeting a nation with rising heart disease rates.</p>
<div class="lb-trans"><p>此次合作標誌着 Cardio Diagnostics 首次在美國以外擴展，目標是一個心臟病發病率上升的國家。</p>
</div><p>The test combines epigenetics, genetics and AI to detect coronary heart disease at a molecular level from a blood sample.</p>
<div class="lb-trans"><p>該測試結合了表觀遺傳學、遺傳學和人工智能，從血樣中檢測分子水平的冠狀動脈心臟病。</p>
</div><h2><strong>Clinical Advantage</strong></h2>
<div class="lb-trans"><h2><strong>臨牀優勢</strong></h2>
</div><p>PrecisionCHD can identify both obstructive and non-obstructive CHD forms usually missed by traditional angiograms.</p>
<div class="lb-trans"><p>PrecisionCHD 能夠識別傳統血管造影通常漏掉的阻塞性和非阻塞性冠狀動脈心臟病形式。</p>
</div><p>Coronary heart disease rates in India range as high as 13% in some urban populations, underscoring urgent screening demand.</p>
<div class="lb-trans"><p>印度的冠狀動脈心臟病發病率在某些城市人羣中高達 13%，凸顯了緊急篩查的需求。</p>
</div><p>Partners have started integrating the test into Dr. Lal PathLabs' clinical and lab network under Indian clinical guidelines.</p>
<div class="lb-trans"><p>合作伙伴已開始將該測試整合到 Dr. Lal PathLabs 的臨牀和實驗室網絡中，遵循印度的臨牀指南。</p>
</div><p>After integration and regulatory alignment, the group expects broader commercial deployment in 2026.</p>
<div class="lb-trans"><p>在整合和監管對接後，該集團預計將在 2026 年實現更廣泛的商業部署。</p>
</div><h2><strong>Executive Insight</strong></h2>
<div class="lb-trans"><h2><strong>高管見解</strong></h2>
</div><p>Cardio Diagnostics CEO and co-founder <strong>Dr. Meesha Dogan</strong> said the tie-up advances equitable access to cutting-edge cardiovascular care.</p>
<div class="lb-trans"><p>Cardio Diagnostics 首席執行官兼聯合創始人 <strong>Dr. Meesha Dogan</strong> 表示，此次合作促進了對尖端心血管護理的公平獲取。</p>
</div><p>Aimil Executive Director <strong>Dr. Mallika Kapur</strong> said the venture strengthens India's access to advanced heart diagnostics.</p>
<div class="lb-trans"><p>Aimil 執行董事 <strong>Dr. Mallika Kapur</strong> 表示，該項目加強了印度對先進心臟診斷的獲取。</p>
</div><p>Dr. Lal PathLabs CEO <strong>Shankha Banerjee</strong> said the test will help clinicians detect disease earlier and tailor treatments.</p>
<div class="lb-trans"><p>Dr. Lal PathLabs 首席執行官 <strong>Shankha Banerjee</strong> 表示，該測試將幫助臨牀醫生更早地發現疾病並量身定製治療方案。</p>
</div><p><strong>CDIO Price Action:</strong> Cardio Diagnostics shares were down 15.77% at $2.35 at the time of publication on Thursday. The stock is trading at a new 52-week low, according to Benzinga Pro data.</p>
<div class="lb-trans"><p><strong>CDIO 股價動態：</strong> Cardio Diagnostics 的股票在週四發佈時下跌 15.77%，報 $2.35。該股票交易於新的 52 周低點，根據 Benzinga Pro 數據。</p>
</div><p><em>Image via Shutterstock</em></p>
<div class="lb-trans"><p><em>圖片來源於 Shutterstock</em></p>
</div>

Cardio Diagnostics 寄希望於印度以擴大其 AI 心臟診斷業務